Amsterdam UMC
Responsive
Amsterdam, The Netherlands
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This study focuses on improving the detection of cancer spread in patients with esophageal cancer. The research evaluates a special imaging method that uses Ferrotran, a contrast agent containing tiny iron particles, which is given through intravenous infusion. This substance helps to better visualize lymph nodes during MRI scans.
The purpose of the study is to determine whether using this special contrast-enhanced imaging technique can provide better information about cancer spread to lymph nodes compared to standard imaging methods. This is important both before and after patients receive initial cancer treatment with chemotherapy and radiation therapy.
During the study, participants will receive a single dose of Ferrotran through an infusion into their vein. The amount given depends on the person's weight. They will then undergo MRI scanning to create detailed images of the lymph nodes. The imaging procedure will be performed twice - once before starting cancer treatment and once after completing it. The total duration of participation in the imaging part of the study is 2 days.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
10 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Amsterdam, The Netherlands
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a contrast agent used in magnetic resonance imaging (MRI). It is injected into the bloodstream and helps to enhance the visibility of lymph nodes during MRI scans. This makes it easier for doctors to see if cancer has spread to the lymph nodes. The particles are very small and are naturally processed by the body after the imaging is complete.
is a combination treatment that uses both chemotherapy (drugs that kill cancer cells) and radiotherapy (radiation treatment) to treat cancer. This therapy is given before surgery (neoadjuvant treatment) to help shrink the tumor and treat possible cancer spread.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.